bluebird bio (BLUE)
(Real Time Quote from BATS)
$1.02 USD
+0.08 (8.19%)
Updated Aug 8, 2024 03:44 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
bluebird bio, Inc. [BLUE]
Reports for Purchase
Showing records 381 - 400 ( 533 total )
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology/Biopharmaceuticals - ASH Recap 2015
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Loss of Expression Is the Concern - Lowering Rating to Neutral
Provider: Roth Capital Partners, Inc.
Analyst: PIROS E
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Treatment Challenges Highlighted by Sickest Patients Likely Increase Time to LentiGlobin Approval, Reiterate OUTPERFORM but Reducing PT
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Week Ahead in Life Sciences - Upcoming Events for the Week of Dec. 7th
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec. 7th
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
We are re-initiating coverage of bluebird bio with a Buy rating and 12-month target price of $121/share.
Provider: Roth Capital Partners, Inc.
Analyst: PIROS E
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Transferring Coverage
Provider: Roth Capital Partners, Inc.
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Nov. 23
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
ASH Late-Breaker: BCMA CAR-T Therapy Demonstrates Anti-Myeloma Activity; We See Read-Through to BLUE
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Uncertainty Not A Friend of the Stock, But LentiGlobin is Here To Stay
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
ASH Abstract Review: Most Severe Beta-Thal Patients Presenting Challenges, Reiterate OUTPERFORM but Trimming PT to $165
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Nov. 2This report contains brief updates on the following: DYAX, ANAC, IRWD, ECYT, FATE, XNCR, RGLS, MGNX, FCSC, SNSS, INFI, MDVN, RPTP, SRPT, XOMA, AGTC, EPZM, BLUE, PTCT, CATB, EPRS, ABUS, ICPT. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Oct 26
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
ASH Abstract Preview, Expecting Volatility Around Conference, but Shares Are Discounting Too Much, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.